Baseline angiotensin receptor blocker–based regimens and first-line chemoimmunotherapy outcomes in patients with hypertension and advanced non-small cell lung cancer

Background Angiotensin receptor blockers (ARBs) act on a pathway implicated in stromal immune suppression. We examined the association between baseline ARB-based treatment and first-line chemoimmunotherapy outcomes in patients with hypertension and advanced non-small cell lung cancer (NSCLC). Methods This single-center retrospective cohort included 312 patients who started a PD-1 inhibitor plus platinum-doublet chemotherapy during 2021–2024. Patients receiving an ARB-based regimen (n = 142) were compared with those receiving a dihydropyridine calcium channel blocker (CCB) regimen without renin–angiotensin–aldosterone system (RAAS) inhibitors (n = 170). Baseline exposure required continuous drug-class use for at least 30 days before treatment initiation. The primary endpoint was progression-free survival (PFS), analyzed using multivariable Cox regression. Sensitivity analyses included propensity score overlap weighting. Objective response rate (ORR), overall survival (OS), early blood pressure and renal function, and adverse events were assessed as exploratory outcomes. Results At a median follow-up of 26.9 months, median PFS was 13.1 months in the ARB-based group and 8.1 months in the CCB comparator group (adjusted hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.56–0.95; P = 0.019). The overlap-weighted HR was 0.75 (95% CI, 0.57–0.99). Objective response rates were 61.3% and 48.2%, respectively (unadjusted P = 0.023; adjusted odds ratio, 1.55; 95% CI, 0.96–2.50; P = 0.072). Median OS was 29.7 versus 23.6 months (adjusted HR, 0.73; 95% CI, 0.53–1.02; P = 0.063). Adjusted week-12 blood pressure and renal function did not differ significantly between groups. Grade ≥3 treatment-emergent adverse events occurred in 28.2% and 27.6% of patients. Conclusion A baseline ARB-based regimen was associated with longer PFS than a CCB regimen without RAAS inhibitors in this hypertensive NSCLC cohort. The adjusted ORR and OS comparisons did not reach statistical significance. These findings support prospective evaluation of ARBs alongside first-line chemoimmunotherapy.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-18
DOI
https://doi.org/10.3389/fphar.2026.2008179
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Baseline angiotensin receptor blocker–based regimens and first-line chemoimmunotherapy outcomes in patients with hypertension and advanced non-small cell lung cancer

Cai Yue, Kai Sun, Fu Yi, Ziyu Jin
2 links
Frontiers in Pharmacology
Lung Cancer Treatments and Mutations
article

Baseline angiotensin receptor blocker–based regimens and first-line chemoimmunotherapy outcomes in patients with hypertension and advanced non-small cell lung cancer

Cai Yue, Kai Sun, Fu Yi, Ziyu Jin
article en

Abstract

Background Angiotensin receptor blockers (ARBs) act on a pathway implicated in stromal immune suppression. We examined the association between baseline ARB-based treatment and first-line chemoimmunotherapy outcomes in patients with hypertension and advanced non-small cell lung cancer (NSCLC). Methods This single-center retrospective cohort included 312 patients who started a PD-1 inhibitor plus platinum-doublet chemotherapy during 2021–2024. Patients receiving an ARB-based regimen (n = 142) were compared with those receiving a dihydropyridine calcium channel blocker (CCB) regimen without renin–angiotensin–aldosterone system (RAAS) inhibitors (n = 170). Baseline exposure required continuous drug-class use for at least 30 days before treatment initiation. The primary endpoint was progression-free survival (PFS), analyzed using multivariable Cox regression. Sensitivity analyses included propensity score overlap weighting. Objective response rate (ORR), overall survival (OS), early blood pressure and renal function, and adverse events were assessed as exploratory outcomes. Results At a median follow-up of 26.9 months, median PFS was 13.1 months in the ARB-based group and 8.1 months in the CCB comparator group (adjusted hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.56–0.95; P = 0.019). The overlap-weighted HR was 0.75 (95% CI, 0.57–0.99). Objective response rates were 61.3% and 48.2%, respectively (unadjusted P = 0.023; adjusted odds ratio, 1.55; 95% CI, 0.96–2.50; P = 0.072). Median OS was 29.7 versus 23.6 months (adjusted HR, 0.73; 95% CI, 0.53–1.02; P = 0.063). Adjusted week-12 blood pressure and renal function did not differ significantly between groups. Grade ≥3 treatment-emergent adverse events occurred in 28.2% and 27.6% of patients. Conclusion A baseline ARB-based regimen was associated with longer PFS than a CCB regimen without RAAS inhibitors in this hypertensive NSCLC cohort. The adjusted ORR and OS comparisons did not reach statistical significance. These findings support prospective evaluation of ARBs alongside first-line chemoimmunotherapy.

Frontiers in PharmacologyVol. 17
Xijing Hospital (CN), Air Force Medical University (CN)
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon